

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Gunnar Tepe

Page 1/6

Tuesday, January 27, 2015

MAIN ARENA 1

09:30 – 11:00

Changing paradigms and future concepts in peripheral interventions

CHAIRMAN:

Dierk Scheinert

Gary Ansel

MODERATOR:

Karl-Ludwig Schulte

Steven Kum

Erich Minar

Andrew Holden

Michael Jaff

Iris Baumgartner

09:30 – 10:00

Drug-coated balloons: Finally proven as the first-line therapy for femoro-popliteal de-novo lesions?

09:30 – 09:35

In.Pact-SFA clinical trial: Update on 1-year data

Gunnar Tepe

09:35 – 09:40

LEVANT II clinical trial: 2-year data

Dierk Scheinert

09:40 – 09:45

My take-home messages from LEVANT II and In.Pact SFA – a critical review

Michael Jaff

09:45 – 09:50

Panel discussion and vote

09:50 – 10:00

Live case transmission from Leipzig part I

10:00 – 11:00

Future prospects for DCB and alternative endovascular concepts

10:00 – 10:05

DCB + atherectomy: The ISAR STATH trial results

Massimiliano Fusaro

10:05 – 10:10

DCB + atherectomy for complex lesions: DEFINITIVE AR – Final data

Gunnar Tepe

10:10 – 10:15

Early look at the VISION Trial: OCT guided atherectomy using Avinger's Pantheris catheter

Arne Schwindt

10:15 – 10:20

The role of vessel preparation – insights from the Heidelberg PANTHER registry

Erwin Blessing

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Gunnar Tepe

Page 2/6

Tuesday, January 27, 2015

- | | |
|---------------|---|
| 10:20 – 10:25 | A future concept for drug delivery: The Mercator Bullfrog technology Dierk Scheinert |
| 10:25 – 10:43 | Live case transmission from Leipzig part II |
| 10:43 – 10:48 | Should all stents promote swirling flow? Thomas Zeller |
| 10:48 – 10:53 | The TOBA-trial 12 months results with the Tack-device for dissection sealing in the SFA Marc Bosiers |
| 10:53 – 11:00 | Biodegradable vascular scaffolds – how far have we come? Iris Baumgartner |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Gunnar Tepe

Page 3/6

Tuesday, January 27, 2015

MAIN ARENA 1

- 13:30 – 15:00** **Symposium: DCB setting the stage for standard of care – an evidence-based review**
supported with an educational grant from Medtronic
CHAIRMAN:
Erich Minar
MODERATOR:
Peter Gaines
Gunnar Tepe
Gary Ansel
Hans Krankenberg
William Gray
- 13:30 – 13:40 IN.PACT in fem-pop TASC A-B and diabetics
Gunnar Tepe
- 13:40 – 14:00 Live case transmission from Leipzig
- 14:00 – 14:10 IN.PACT global sub-analysis update: TASC C-D lesions
Gary Ansel
- 14:10 – 14:20 DCB and ISR: Insights from FAIR study
Hans Krankenberg
- 14:20 – 14:30 Are all DCB equal?
William Gray
- 14:30 – 14:50 Live case transmission from Cotignola
- 14:50 – 15:00 IN.PACT role in SFA: Critical overview of modern endovascular therapies
Frank Vermassen

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Gunnar Tepe

Page 4/6

Tuesday, January 27, 2015

MAIN ARENA 1

- 15:00 – 16:30** **Current concepts and advances for long femoropopliteal lesions and in-stent restenosis**
CHAIRMAN:
Tony Das
MODERATOR:
Jörn Balzer
Francesco Liistro
Peter Gaines
Marc Bosiers
Sabine Steiner
Michael Werk
Roberto Gandini
- 15:00 – 15:07 What works best for long SFA disease? A review of the evidence
Marc Bosiers
- 15:07 – 15:12 After 10.000+ DCB: How has this technology changed our clinical practice for complex SFA lesions?
Andrej Schmidt
- 15:12 – 15:19 One-year follow-up of the DEBAS STUDY
Patrice Mwipatayi
- 15:19 – 15:26 Is the combination of DCB and bare metal stents as effective as DES? The BIOLUX 4EVER trial
Marc Bosiers
- 15:26 – 15:42 Live case transmission from Dendermonde
- 15:42 – 15:47 The endoluminal bypass – the best solution for long lesions and ISR?
Peter Soukas
- 15:47 – 15:52 The Leipzig experience with DCB, conventional, and interwoven nitinol stents for complex SFA disease
Sabine Steiner
- 15:52 – 16:15 Live case transmission from Leipzig
- 16:15 – 16:20 Excimer laser atherectomy for in-stent restenosis: Results of the EXCITE trial
Eric Dippel

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Gunnar Tepe

Page 5/6

Tuesday, January 27, 2015

- | | |
|---------------|--|
| 16:20 – 16:25 | The Copa Cabana study: DEB vs. POBA in in-stent restenosis Gunnar Tepe |
| 16:25 – 16:30 | The cost economic value of DCB Konstantinos Katsanos |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Gunnar Tepe

Page 6/6

Thursday, January 29, 2015

DISCUSSION FORUM

- 12:30 – 13:30** **The great debate: Are all DCB equal?**
CHAIRMAN:
Michael Jaff
Dierk Scheinert
DISCUSSANT:
Gunnar Tepe
Renu Virmani
Stephan Duda
Marianne Brodmann
- 12:30 – 12:37 There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!
Gunnar Tepe
- 12:37 – 12:44 Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges –
Results have been substantially affected by trial design
- 12:44 – 12:51 The relevance of Paclitaxel dose and coating for efficacy and safety
Renu Virmani
- 12:51 – 12:58 Whats next to come in the drug delivery space: Ongoing DCB programmes
Stephan Duda
- 12:58 – 13:05 Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions
Erich Minar
- 13:05 – 13:12 DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are
continuing
Marianne Brodmann
- 13:12 – 13:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.